An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...
A cancer diagnosis often comes with overwhelming emotions and a flood of unfamiliar medical terms that can spark even more fear. But understanding these terms can help you feel more in control of your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback